PRF Technologies Ltd. (Nasdaq: PRFX) released expanded preclinical results for its lead product candidate, PRF-110, comparing it to ZYNRELEF, an approved extended-release pain management product made by Heron Therapeutics, Inc.

The study was conducted in a validated porcine post-operative pain model using von Frey methodology. According to the company, PRF-110 demonstrated analgesic efficacy comparable to ZYNRELEF, as measured by reductions in mechanical sensitivity.

The expanded results also cover pharmacokinetic and tissue-distribution data. PRF-110 showed a slower absorption rate relative to ZYNRELEF, along with greater retention in local tissue and higher local tissue exposure. Both formulations demonstrated sustained systemic and local drug levels during the study period.

PRF-110 is an oil-based, extended-release formulation of ropivacaine intended to be deposited directly into the surgical wound bed prior to closure. The product is being developed to provide prolonged post-operative pain relief from a single administration, with the goal of reducing reliance on opioids after surgery.

"Its pharmacokinetic profile—characterized by slower absorption and enhanced local tissue retention—combined with analgesic efficacy comparable to an approved benchmark, potentially positions PRF-110 to address a significant unmet need in improving post-surgical recovery and patient comfort," said Efi Cohen-Arazi, Chief Executive Officer of PRF Technologies.

PRF Technologies stated it plans to continue advancing PRF-110 through additional studies to assess safety, efficacy, and clinical utility across broader surgical settings. The company noted that ZYNRELEF was used solely as a comparator and that PRF Technologies has no affiliation with Heron Therapeutics.